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Tbjective: A composite stentless valve might be less obstructive than a preparation
ncorporating the porcine right coronary muscle bar. The aim of this study was to
ompare early hemodynamic function in a prospective series of 78 patients ran-
omized to receive either a Toronto or Cryolife O’Brien stentless valve.
ethods: Echocardiography was performed early after surgery, between 3 and 6
onths, and at 1 year after surgery.
esults: The groups were matched demographically. The Cryolife O’Brien valve
as significantly less obstructive in terms of effective orifice area (1.81 vs 1.30 cm2;
 .0001), mean pressure difference (7.1 vs 11.7 mm Hg; P  .0001), and peak
elocity (1.7 vs 2.2 m/s) assessed at 1 year (P  .001). Bypass time was 91 (SD 22)
inutes for the Cryolife O’Brien compared with 125 (SD 22) minutes (P  .0001)
or the Toronto. There was a higher incidence of paraprosthetic regurgitation in the
ryolife O’Brien valve (16.7% vs 3.2%). Mortality and clinical events were similar.
onclusion: The composite valve was less obstructive than the porcine valve,
uggesting that stentless valves cannot be considered as a homogeneous class.
ll replacement valves are obstructive compared with normal native valves,1
but the orifice area available for flow is expected to be larger with a
stentless than a stented valve. Although this was confirmed in early stud-
es,2,3 larger randomized studies4-7 show conflicting results. It is possible that
pparent discrepancies are partly caused by differences in the comparator stented
alve, as there is some evidence that pericardial valves are hemodynamically
uperior to porcine valves.8 However, it is also possible that a stentless valve
anufactured from a whole porcine aortic root is more obstructive than a composite
tentless valve lacking the muscle bar at the base of the right coronary cusp.
The aim of this study was therefore to compare hemodynamic function in
atients prospectively randomized to either the Toronto (St Jude Medical Inc,
inneapolis MN) porcine stentless valve or the Cryolife O’Brien (Cryolife O’Brien
nternational, NW Kennesaw, GA) tricomposite stentless valve.
aterials and Methods
atients
total of 80 consecutive patients scheduled to have single bioprosthetic valve replacement
n the aortic position were recruited. The population sizes were calculated to detect a
ifference in mean effective orifice area of 0.2 cm2 and standard deviation of 0.3 cm2 with
0% power. A random number sequence with a block of 16 was applied at the time of listing
or surgery. However, 2 patients randomized to receive a Toronto required a stented biologic
alve because of dilatation of the aortic root. The study group, therefore, comprised 78
atients. The mean age was 73 (range 55-88) years and 39 (50%) were men. Demographic
etails are given in Table 1. The study was accepted by the Local Committee on Ethical
ractice, and all patients gave written consent.
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A
CDurgery
he Toronto valve was chosen as the porcine stentless replace-
ent. It consists of a preparation of porcine aortic root sculpted to
ccommodate the coronary ostia and lined externally with Dacron.
he valves were implanted using a subcoronary technique with
nterrupted sutures for the lower suture line at the level of the
nnulus joining the lower midpoints of previous cuspal attachment
nd passing across the intercommissural triangles. The porcine com-
issures were suspended independently, and a running polypro-
ylene suture was used for the upper suture line. The Cryolife
’Brien model 300 valve was chosen as the composite stentless
alve. It is composed of 3 individual noncoronary porcine cusps
nd has no Dacron lining. The profile is lower than for the Toronto,
nd it is sewn using a single continuous suture to the aortic wall
ust above the annulus.9
The native aortic valve was completely excised with aggressive
ebridement of all calcium to leave a smooth tissue annulus. Both
alve types were sized from the sinotubular junction as discussed
y David and colleagues10 using a cylindrical independent sizer.
his had been confirmed to correspond to the sizers provided by
he 2 manufacturers. The patient tissue annulus was also measured
sing the independent sizer to exclude oversizing. In most cases, a
alve of 1 label size larger than the patient tissue annulus diameter
as selected,11 but in the presence of a large sinotubular junction,
valve of 2 label sizes larger was occasionally used. However, if
he sinotubular diameter was more than 2 sizes larger than the
atient tissue annulus diameter, a stented valve was implanted
nstead and the patient was excluded. This occurred on 2 occa-
ions. Aortoplasty or enlargement of the sinotubular junction was
ot required. Standard operative procedures were used with a
edian sternotomy, cardiopulmonary bypass, cooling to 32°C, and
old blood cardioplegia for myocardial preservation.
chocardiography
tudies were performed immediately before discharge, at the first
ostoperative visit at 6 weeks, then between 3 and 6 months, and
gain at 1 year. Five patients refused echocardiography at 3 to 6
onths and 1 was in hospital elsewhere, and 3 patients refused
estudy at 1 year. Measurements were made as recommended by
he American Society of Echocardiography12 over 3 cycles in
inus rhythm or over 6 cycles in atrial fibrillation. Left ventricular
Abbreviations and Acronyms
ANOVA analysis of variance
CSA  left ventricular outflow cross-sectional area
P  pressure difference
EOA  effective orifice area
LV  left ventricular
LVDD  left ventricular diastolic diameter
NYHA  New York Heart Association
v1  subaortic peak velocity
v2  transaortic peak velocity
VTI1  subaortic velocity integral
VTI2  aortic velocity integralLV) outflow diameter was measured from inner to inner edge just v
046 The Journal of Thoracic and Cardiovascular Surgery ● Aprelow the replacement aortic valve in a parasternal long-axis view
rozen in systole. The largest of 3 measurements was used. Re-
urgitant jets were localized, then graded by a combination of the
et height and the density, and pressure half-time of the aortic
egurgitant signal on continuous wave Doppler. Moderate regur-
itation was defined by a jet height between 25% and 65% of the
utflow diameter with a pressure half-time longer than 300 ms.
ild regurgitation was defined by a jet height less than 25% of the
utflow diameter and a complete, low-intensity continuous wave-
orm with pressure half-time longer than 500 ms. Trivial regurgi-
ation was defined by a thin, low-momentum jet ending close to the
alve with an incomplete continuous waveform. No jet in this
tudy was found to be severe.
alculations
he following calculations were performed: (1) effective orifice
rea (EOA) by the continuity equation (EOA in cm2)  CSA 
TI1/VTI2 where CSA is LV outflow cross-sectional area (cm2)
alculated from the diameter assuming circular cross section, VTI1
s subaortic velocity integral (cm), and VTI2 is aortic velocity
ntegral (cm); (2) peak pressure difference across the aortic valve
peak P in mm Hg)  4 (v22  v12) where v2 is transaortic peak
elocity (m/s) and v1 is subaortic peak velocity (m/s); (3) mean
ressure difference across the aortic valve (mean P in mm Hg)
ortic mean P subaortic mean P; (4) LV mass (g) 0.83 (left
TABLE 1. Demographic comparison of patients receiving
Toronto or Perimount valves (mean  standard deviation)
Cryolife O’Brien
(n  40)
Toronto
(n  38)
Age (y), mean (range) 73 (55-86) 73 (57-88)
Male:female 21:18 18:21
BSA (kg/m2) 1.76  0.20 1.77  0.19
LV outflow diameter (mm) 20.5 (1.7) 19.8  1.4
Etiology
Aortic stenosis 33 33
Aortic regurgitation 3 4
Mixed AS and AR 3 2
Previous AVR 0 0
Previous CABG 1 0
Associated procedures
Combined CABG 15 16
Aortic root replacement 0 1
Mitral valve repair 0 1
Preoperative NYHA class
I 3 4
II 16 11
III 17 20
IV 1 1
Preoperative LVEF  35% 4 3
Functionally bicuspid valve 5 1
AR, Aortic regurgitation; AS, aortic stenosis; AVR, aortic valve replace-
ment; BSA, body surface area; CABG, coronary artery bypass grafting; LV,
left ventricular; LVEF, left ventricular ejection fraction; NYHA, New York
Heart Association.entricular diastolic diameter [LVDD]  septal thickness  pos-
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A
CDerior wall thickness)3  (LVDD)3. LV mass and EOA were
ndexed to body surface area.
nalysis
he mean and standard deviation values were calculated for vari-
bles that were approximately normally distributed and the median
nd range for those that were skewed. Comparisons were made
etween valve types using the unpaired t test or nonparametric
ann–Whitney U test as appropriate. The hemodynamic results
ere compared over the 4 postoperative visits using 1-way anal-
sis of variance (ANOVA). The incidence of regurgitation was
ompared using Fisher exact test as the numbers in some catego-
ies were expected to be small. Standard definitions of clinical
vents were used.13 Sizing was compared by plotting the LV
utflow diameter measured by echocardiography against the label
igure 1. LV outflow tract diameter (mean and 95% confidence
nterval) for each label size by valve type. LV, left ventricular.
ABLE 2. Hemodynamic results for whole Cryolife O’Brien
ariable Preop Postop
ryolife O’Brien group
EOA (cm2) 0.80 0.47 1.61 0.
VTI1 (cm) 20.9 5.6 16.5 4.
Vmax (m/s) 4.1 1.0 2.1 0.
Mean P (mm Hg) 43.3 19.1 9.9 6.
oronto group
EOA (cm2) 0.76 0.50 1.31 0.
VTI1 (cm) 19.9 5.9 15.1 4.
Vmax (m/s) 4.1 1.1 2.5 0.
Mean P (mm Hg) 44.3 22.5 15.29  8.
P, Transaortic pressure difference; EOA, effective orifice area by the
ransaortic velocity; VTI1, subaortic velocity time integral.
The Journal of Thoracicize for each valve design. Analyses were performed using the
tatistical package social sciences version 11.5.1.
esults
he groups were similar with respect to demographic char-
cteristics (Table 1). The mean label size was 25.05 (stan-
ard deviation 2.62) for the Cryolife O’Brien and 24.80
2.62; P  .66) for the Toronto valves. LV outflow tract
iameter was similar for both valve types for label sizes 21
hrough 25, and approximately 2 mm smaller for the To-
onto at label size 27 and 29 (Figure 1). Crossclamp time for
he Cryolife O’Brien group was 67 (SD 12) minutes, which
as statistically shorter than for the Toronto group at 102
SD 21) minutes (P  .0001). Total bypass time for the
ryolife O’Brien group was 91 (SD 22) minutes compared
ith 125 (SD 22) minutes for the Toronto group (P 
0001). Two patients died in the early postoperative period
2.6%), 1 in each group. There were 6 deaths between 30
ays and 1 year, 4 in the Toronto group and 2 in the Cryolife
’Brien group. One patient developed endocarditis in each
roup, which was fatal for the patient in the Cryolife
’Brien group but not fatal for the patient in the Toronto
roup. There were no thromboembolic events and no valve
hromboses.
There were minor changes in results over time (Table 2),
ut these did not attain statistical significance within each
roup. At 1 year, the effective orifice area was 1.81 (0.50)
m2 for the Cryolife O’Brien and 1.30 (0.42) cm2 for the
oronto group (P  .0001; Table 2). Patient–prosthesis
ismatch defined by indexed effective orifice area  0.8
m2/m2 occurred in 16 patients in the Toronto group and 4
atients in the Cryolife group (P  .0001). The peak
ransaortic velocity was 1.7 (0.4) m/s for the Cryolife
’Brien group and 2.2 (0.5) m/s for the Toronto group (P
0001), and the mean gradient for the Cryolife O’Brien
roup was 7.1 (3.7) mm Hg compared with 11.6 (5.7) mm
g (P  .001) for the Toronto group. For comparison with
p and whole Toronto group (mean  standard deviation)
6 wk 3-6 mo 1 y
1.83 0.48 1.82  0.51 1.81  0.50
19.3 4.5 19.7  4.9 19.4  4.1
1.9 0.5 1.8  0.5 1.7  0.4
8.4 4.8 7.6  4.4 7.1  3.7
1.42 0.41 1.47  0.46 1.30  0.42
18.3 3.5 19.4  4.1 19.5  4.1
2.2 0.5 2.1  0.5 2.2  0.5
11.4 4.9 10.9  5.2 11.6  5.7
nuity equation; Preop, preoperative; Postop, postoperative; Vmax, peakgrou
50
01
6
5
54
0
7
8
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1
A
CDhe literature, hemodynamic results by label size are given
or 3-6 months and 1 year in Table 3.
There was no change in the incidence or degree of
egurgitation during the short study period. At 1 year there
ABLE 3. Hemodynamic results at 3-6 and 12 months dis-
layed for convenience by label size* (mean  standard
eviation)
Toronto
Cryolife
O’Brien P
-6 mo (n) 34 35
°21 mm (n) 6 3
EOA (cm2) 0.87 0.11 1.16  0.17 .082
Vmax (m/s) 2.6  0.5 2.5  1 .903
Mean P (mm Hg) 17.2 4.4 16.8  7.7 .942
23 mm (n) 9 12
EOA (cm2) 1.4  0.3 1.6  0.3 .293
Vmax (m/s) 2.2  0.5 2.0  37 .336
Mean P (mm Hg) 12.1 5.3 8.6  3.2 .101
25 mm (n) 9 9
EOA (cm2) 1.7  0.5 2.0  0.4 .361
Vmax (m/s) 2.0  0.4 1.7  0.4 .05*
Mean P (mm Hg) 9.1 2.9 6.1  2.5 .03*
27 mm (n) 4 3
EOA (cm2) 1.6  0.4 2.2  0.5 .159
Vmax (m/s) 2.1  0.6 1.5  0.2 .110
Mean P (mm Hg) 9.7 5 5.0  0.7 .156
29 mm (n) 6 8
EOA (cm2) 1.8  0.3 2.2  0.4 .088
Vmax (m/s) 1.7  0.2 1.6  0.3 .445
Mean P (mm Hg) 6.4 1.7 5.3  1.3 .192
2 mo (n) 31 36
21 mm (n) 6 3
EOA (cm2) 1.0  0.1 1.1  0.3 .392
Vmax (m/s) 2.7  0.3 2.0  0.5 .122
Mean P (mm Hg) 16.7 3.2 13.1  5.1 .353
23 mm (n) 6 13
EOA (cm2) 1.3  0.3 1.6  0.4 .082
Vmax (m/s) 2.4  0.6 1.8  0.5 .063
Mean P (mm Hg) 14.4 8.6 7.3  4.3 .143
25 mm (n) 9 9
EOA (cm2) 1.4  0.3 1.9  0.4 .005*
Vmax (m/s) 2.1  0.4 1.7  0.3 .043*
Mean P (mm Hg) 10.0 4.2 6.2  2.3 .034*
27 mm (n) 4 4
EOA (cm2) 1.6  0.3 2.0  0.2 .04*
Vmax (m/s) 2.0  0.4 1.8  0.2 .454
Mean P (mm Hg) 9.6 4.1 7.2  1.2 .328
29 mm (n) 6 7
EOA (cm2) 2.1  0.7 2.2  0.5 .662
Vmax (m/s) 1.7  0.3 1.6  0.3 .437
Mean P (mm Hg) 7.0 2.6 5.2  2.0 .237
P, Transaortic pressure difference; EOA, effective orifice area by the
ontinuity equation; Vmax, peak transaortic velocity. *Valves of the same
abel size are not biologically comparable.as mild regurgitation through the valve in 2 (6.5%) pa- d
048 The Journal of Thoracic and Cardiovascular Surgery ● Aprients in the Toronto group and 2 (5.6%) patients in the
ryolife O’Brien group. None had moderate or severe re-
urgitation. There was mild paraprosthetic regurgitation in
(16.7%) patients in the Cryolife O’Brien group but none
n the Toronto group, while there was moderate parapros-
hetic regurgitation in 1 (3.2%) patient in the Toronto group
nd none in the Cryolife O’Brien group. Of the 5 patients
ith functionally bicuspid native valves who received a
ryolife O’Brien valve, only 1 had mild paraprosthetic
egurgitation, and the single patient receiving a Toronto
alve had no regurgitation. There was no significant differ-
nce in the incidence of regurgitation using Fisher exact
est. There was no significant difference in LV mass index
r indices of systolic function between the 2 valve types at
ny point after surgery (Table 4). New York Heart Associ-
tion (NYHA) class was similar in the 2 groups at 1 year,
ith 30 of 37 (81%) patients in the Cryolife group and 27 of
1 (87%) patients in the Toronto group in NYHA I, 6 (16%)
nd 3 (10%) patients, respectively, in NYHA II, 1 patient in
ach group in NYHA III, and none in NYHA IV.
iscussion
tentless xenograft replacement valves are usually consid-
red as a homogeneous class. This study suggests that differ-
nces within the class may be important as the Cryolife
’Brien valve was hemodynamically superior to the To-
onto valve.
This is likely to be related predominantly to the differ-
nce in design and implantation site. The Toronto valve is
repared from a whole porcine aortic root with the possi-
ility of a reduction in the compliance of the annulus and
ncreased stiffness of the paracommissural parts of the cusps
aused by the retained muscle bar at the base of the right
oronary cusp and the use of a Dacron lining. By compar-
son, the Cryolife O’Brien valve has no Dacron lining and is
omposed of 3 noncoronary cusps and therefore has no
uscle bar. Furthermore, the Toronto valve is sewn with the
ower sutures at the annulus, and the Cryolife O’Brien valve
s sited just above the annulus. Similar results were shown
n a comparison of the cryopreserved homograft and Prima,14
Edwards Lifesciences, Irvine, Calif) which is a porcine
reparation with the septal muscle shelf removed but with a
acron-covered annulus. The mean pressure drop was 5
m Hg in the homograft group compared with 12 mm Hg
n the Prima group. By contrast, another study15 found a
imilar pressure drop in homografts and the Toronto stent-
ess valve, but this was measured only a few hours after
urgery using a regression equation to calculate pressure
ifference. In the present study, there were small differences
n the size of the aorta in favor of the Cryolife valve. The
ean label size, which reflects sinotubular junction diame-
er, differed by only 0.2 mm. However, the LV outflow
iameter on echocardiography, which reflects patient tissue
il 2007
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A
CDnnulus diameter, was approximately 2 mm smaller for the
oronto than for the Cryolife valves in the 27-mm and
9-mm sizes, although similar for the other sizes (Figure 1).
There are no significantly discrepant results compared
ith published information on the Cryolife O’Brien
alve10,12,16-20 and for the Toronto valve.2,3,6,21,22 How-
ver, there is significant variation in the methodology and
ndings of previously published studies such that until our
andomized comparison, it has not been possible to draw
onclusions about the relative hemodynamic performance
f the 2 valve types. We showed a fall in gradient between
he postoperative study and 1 year for both valve types, as
lso shown by others.18,19 However, these changes were not
ignificant on ANOVA. The hemodynamic differences were
ot associated with differences in NYHA class, LV mass
egression, or clinical events.
The Cryolife O’Brien valve has a relatively large coap-
ation region. This avoids the tendency of valve prepared
rom a whole root to distort leading to regurgitation through
he valve. We showed a low incidence of regurgitation
hrough the valve in agreement with other authors,18,20
lthough this was no different from the regurgitation
hrough the Toronto valve.23 Previous work has shown a
lightly higher incidence of regurgitation through the To-
onto valve.24-27 The incidence of paraprosthetic regurgita-
ion was higher for the Cryolife O’Brien valve than for the
oronto valve, although this difference did not attain statis-
ical significance. The presence of regurgitation was not asso-
iated with native bicuspid valve disease, and in neither valve
ype was the regurgitation graded more than moderate.
imitations
his study compared patients of similar body size and
inotubular junction diameter as measured by an indepen-
ent sizer. The echocardiographic LV outflow diameters,
eflecting tissue annulus diameters, were similar for the
1-mm through 25-mm valves but smaller for the Toronto
han the Cryolife O’Brien for the 27- and 29-mm valves.
ABLE 4. Measures of LV structure and function (mean 
Toronto
reoperative LV mass index (g/m2) 135 48
V mass index at 3-6 mo (g/m2) 97  32
V mass index at 12 mo (g/m2) 105 46
reoperative FS (%) 31 12
S at 3-6 mo (%) 38 9
S at 12 mo (%) 39 15
reoperative VTI (cm) 19.9 6.0
TI at 3-6 mo (cm) 19.3 4.0
TI at 12 mo (cm) 19.5 4.1
I, Confidence interval; FS, fractional shortening; LV, left ventricular; LVOhis suggests a slight weighting in favor of the Cryolife
The Journal of Thoracic’Brien but is insufficient to explain the overall better
erformance as results were better at the smaller as well
s the larger sizes. The study was powered only to com-
are hemodynamic function, and the trend toward a higher
ncidence in paraprosthetic regurgitation in the Cryolife
’Brien valves might become significant with larger popu-
ation sizes. This study was also concerned with early re-
ults and cannot exclude differences in durability or late
vents. Furthermore, the Toronto valves were implanted in
subcoronary position, and hemodynamic function is ex-
ected to be better with implantation as a total root
eplacement.
onclusions
his study showed superior forward flow characteristics
ith a trend toward more paraprosthetic regurgitation for
he Cryolife O’Brien valve compared with the Toronto
tentless valve. This suggests that stentless valves should
ot be considered as a uniform class but must be subdivided
ccording to design and implantation site. The Cryolife
’Brien valve is a tricomposite supra-annular valve, and the
oronto valve for this study was implanted in a subcoronary
osition.
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